Neuregulin-1 immunoglobulin-like domain mutant mice: Clozapine sensitivity and impaired latent inhibition

NeuroReport

Volumn 16, Issue 3, 2005, Pages 271-275

  Rimer, Mendell ^a   Barrett, Douglas W ^a   Maldonado, Monica A ^a   Vock, Vita M ^a   Gonzalez Lima, F ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Clozapine; Latent inhibition; Neuregulin 1; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GENOMIC DNA; IMMUNOGLOBULIN; NEU DIFFERENTIATION FACTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENETIC SUSCEPTIBILITY; LATENT INHIBITION; LOCOMOTION; MENTAL DISEASE; MOUSE; MUTANT; NONHUMAN; OPEN FIELD BEHAVIOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; RUNNING; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; IMMUNOGLOBULINS; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; NEURAL INHIBITION; NEUREGULIN-1; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RUNNING; SCHIZOPHRENIA;

EID: 14944350075     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200502280-00014     Document Type: Article

References (23)

1. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71:877-892.
2. Corvin AP, Morris DW, McGhee K, Schwaiger S, Scully P, Quinn J et al. Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol Psychiatry 2004; 9:208-213.
3. Li T, Stefansson H, Gudfinnsson E, Cai G, Liu X, Murray RM et al. Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/ Scottish risk haplotype. Mol Psychiatry 2004; 9:698-704.
4. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003; 72:83-87.
5. Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry 2003; 8:485-487.
6. Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL et al. Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry 2003; 8:706-709.
7. Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol 2001; 11:287-296.
8. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284:14-30.
9. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development [see comments] [published erratum appears in Nature 1995; 378:753]. Nature 1995; 378:386-390.
10. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development [see comments] [published erratum appears in Nature 1995; 378:753]. Nature 1995; 378:386-390.
11. Kramer R, Bucay N, Kane DJ, Martin LE, Tarpley JE, Theill LE. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci USA 1996; 93:4833-4838.
12. Wolpowitz D, Mason TB, Dietrich P, Mendelsohn M, Talmage DA, Role LW. Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron 2000; 25:79-91.
13. Gerlai R, Pisacane P, Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res 2000; 109:219-227.
14. Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE et al. Isoform-specific expression and function of neuregulin. Development 1997; 124:3575-3586.
15. Sandrock AW Jr, Dryer SE, Rosen KM, Gozani SN, Kramer R, Theill LE et al. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 1997; 276:599-603.
16. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zheng H et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviours related to schizophrenia. Proc Natl Acad Sci USA 2003; 100:8987-8992.
17. Liu X, Hwang H, Cao L, Wen D, Liu N, Graham RM et al. Release of the neuregulin functional polypeptide requires its cytoplasmic tail. J Biol Chem 1998; 273:34335-34340.
18. Liu X, Hwang H, Cao L, Buckland M, Cunningham A, Chen J et al. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci USA 1998; 95: 13024-13029.
19. Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci 2001; 24:527-533.
20. Cohen E, Sereni N, Kaplan O, Weizman A, Kikinzon L, Weiner I et al. The relation between latent inhibition and symptom-types in young schizophrenics. Behav Brain Res 2004; 149:113-122.
21. Baruch I, Hemsley DR, Gray JA. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 1988; 176:598-606.
22. Lubow RE, Gewirtz JC. Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull 1995; 117:87-103.
23. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psychiatry Suppl 1999; 37:16-18.